medigraphic.com

2005, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2005; 43 (6)

Microalbuminuria in Patients with Type 2 Diabetes

Leza-Torres O, Briones-Lara E, González-Madrazo MA, De la Cruz-Martínez MC, Ramos-Dávila E

Language: Spanish
References: 21
Page: 487-493
PDF size: 145.99 Kb.


ABSTRACT

Objetive: To identify microalbuminuria in pa-tients with type 2 diabetes.
Material and methods: A descriptive cross-section study was made in patients with type 2 diabetes with more than a year of evolution. Microalbuminuria was defined as the presence of 30 to 300 mg of albumin in urine of 24 hours. The socio-demographic characteristics, type of diet, exercise, type of antihypertensive and oral antihyperglycemic agents were analyzed. Basal glycemia after one and two months, and renal state were assessed.
Results: Of 301 type 2 diabetic patients, 251 had microalbuminuria. The mean age was 57.2 years old. Women predominated over men (1.4:1). The mean for diabetes evolution was nine years. The complication with more frequency was hypertensive cardiopathy 78.1 %. A medium protein diet was present in 49 %. 62.2 % exercised and 40.2%, less than 30 minutes. Mean GFR with creatinine clearance was 83.3 + 32 mL/min. 98 % of the cases received oral antihyper-glycemic agents. Basal glycemia, after one and two months, was, on average, 171.8 mg/dL, 190.1 mg/dL, and 217.4 mg/dL. 74.5 % of the patients had hyperglycemia in the first mea-suring, 79.3 % in the second one, and 70.5 % in the third one.
Conclusions: The prevalence of microalbumi-nuria was greater than the reported in literature (85.3 %). A poor control of glycemia was showed.


REFERENCES

  1. Olais G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Morelos, México: Instituto Nacional de Salud Pública; 2003.

  2. 2. Poirier S. Preserving the diabetic kidney. J Fam Practice 1998;4(1):21-28.

  3. 3. Grupo de Diabetes de la Sociedad Andaluza de Medicina Familiar y Comunitaria. Nefropatía diabética. 1996-1998. Disponible en: http://www.cica.es/~samfyc/nefropat.htm.

  4. 4. Mykkänen L, Haffner SM, Kuusisto J, Pyorälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes 1994;43(4):552-557.

  5. 5. Álvarez-Espinoza MG, Verduzco-Jimenéz R, Juárez-Baizabal MC, Flores-Chávez MC, Cárdenas–Cornejo I, González-Bárcena D. Comparación de pruebas para detección de microalbuminuria en pacientes con diabetes mellitus tipo 2. Rev Mex Patol Clin 2000;47(2):107-109.

  6. 6. Moegensen CE. Microalbuminuria and hiperten-sion with focus on type 1 and type 2 diabetes. J Inter Med 2003;254:45-66.

  7. 7. Keane WF, Brenner BM, de Zeeuw D, Grunfeld J, Mcgill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003;63(4):1499–1507.

  8. 8. Ritz E, Tarng D. Renal disease in type 2 diabetes. Nephrol Dial Transplant 2001;16(Supl 5):11-18.

  9. 9. Álvarez-Echevarría R, Padilla-González JC, Crespo-Valdés N. Microalbuminuria y su asocia-ción a otros factores pronósticos, en pacientes diabéticos no insulino dependientes tipo 2. Rev Mex Patol Clin 1999;46(4):249-254.

  10. Halabe BA. Microalbuminuria. Utilidad clínica. An Med Asoc Med Hosp ABC 1999;44(2):82-85.

  11. Marshall SM. Recent advances in diabetic nephro-pathy. Clin Med 2004;4(3):277-282.

  12. Leyva-Jiménez R, Álvarez-Aguilar C, López-Molina MG. Función renal en diabéticos tipo 2 deter-minada por fórmula Cockcroft-Gault y depuración de creatinina. Rev Med IMSS 2004;42(1):5-10.

  13. Gross JL, Azevedo MJ, Silverio SP, Canana LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention and treatment. Diabetes Care 2005;28(1):176-188.

  14. Viberti G. Microalbuminuria, la clave para las com-plicaciones diabéticas. Rev Nefrol Dial Traspl 1994;36:23-31.

  15. Mattock MB, Morris NJ, Viberti G, Keen H, Fitzgerald AP, Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992;41(6):736-741.

  16. Sociedad Mexicana de Nutrición y Endocrinología, Asociación de Medicina Interna de México, Socie-dad de Nutriología. Consenso para la prevención de las complicaciones crónicas de la diabetes tipo 2. Rev Invest Clin 2000;52(3):325-363.

  17. Luño J. Prevención de la neuropatía diabética. Nefrol Mex 2000;21(4):185-190.

  18. Kawazu S, Tomono S, Shimizu M, et al. The relationship between early diabetic nephropathy and control of plasma glucose in non-insulin-dependent diabetes tipo 2: the effect of glycemic control on the development and progression of diabetic nephropathy in an 8-year follow-up study. J Diabetes Complications 1994;8(1):13-17.

  19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  20. Ritz E, Orth SR. Primary care: Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341(15):1127-1133.

  21. Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med 2004;21:4-17.




2020     |     www.medigraphic.com